TAK-981 treatment increases M1-like/M2-like ratio in TAM and activates tumor-infiltrated NK cells in OCI-Ly10 xenografts. (A) Schematic diagram of study design. Tumors from 7.5 mg/kg TAK-981 (administered on day 1, 4, and 8)- and/or 1 mg/kg rituximab (administered on day 1 and 8)- treated OCI-Ly10 tumor-bearing mice on day 5 or day 9 were analyzed. (B) Proportion of CD11b⁺Ly6G⁻Ly6C^lowF4/80⁺ TAM, NKp46⁺ NK cells, CD11b⁺Ly6G⁻Ly6C^high monocytes, or CD11b⁺Ly6G⁺Ly6C^int neutrophils on day 5 (mean with SD; n = 5 mice per group in the representative study, 2-tailed unpaired Welch’s t test). (C) Proportion of CD11b⁺Ly6G⁻Ly6C^lowF4/80⁺ TAM, NKp46⁺ NK cells, CD11b⁺Ly6G⁻Ly6C^high monocytes, or CD11b⁺Ly6G⁺Ly6C^int neutrophils on day 9 (mean with SD; n = 5 mice per group, 2-tailed unpaired Welch’s t test). (D) Left, representative flow cytometry scatter plots of CD86/CD206. Right, proportion of M1-like (CD86⁺CD206⁻) TAM or M2-like (CD86⁻CD206⁺) TAM in tumors on day 5. (E) Left, representative flow cytometry scatter plots of FCGR4/FSC-H. Right, proportion of FCGR4⁺ TAM in tumors on day 5. (F) Proportion of CD69⁺ or IFNγ⁺ NK cells in tumors on day 5. Box plot center, box, and whiskers correspond to median, IQR (interquartile range), and 1.5 times IQR, respectively (n = 5 mice per group in the representative study, 2-tailed unpaired Welch’s t test). Two similar experiments were performed. SD, standard deviation.